We evaluated potential prognostic biomarkers, including sex, age at diagnosis; tumor sidedness; previous lines of therapy; MSI status; liver, peritoneal, and lung metastases; ECOG PS; CEA; and CA19.9. This evidence concerns the gene CEACAM5 and neoplasm.